Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers
Abstract SARS-CoV-2, the virus responsible for COVID-19, has caused a global pandemic.
Antibodies can be powerful biotherapeutics to fight viral infections. Here, we use the human …
Antibodies can be powerful biotherapeutics to fight viral infections. Here, we use the human …
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …
SARS-CoV-2 spike S2-specific neutralizing antibodies
CJ Li, SC Chang - Emerging Microbes & Infections, 2023 - Taylor & Francis
Since the onset of the coronavirus disease 2019 (COVID-19), numerous neutralizing
antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment
D Li, GD Sempowski, KO Saunders… - Annual review of …, 2022 - annualreviews.org
Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
[HTML][HTML] A potently neutralizing antibody protects mice against SARS-CoV-2 infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for millions
of infections and hundreds of thousands of deaths globally. There are no widely available …
of infections and hundreds of thousands of deaths globally. There are no widely available …
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
V Dussupt, RS Sankhala, L Mendez-Rivera… - Nature …, 2021 - nature.com
Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …
Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective
Y Huang, H Sun, H Yu, S Li, Q Zheng… - Antibody …, 2020 - academic.oup.com
The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
Antibodies are a principal determinant of immunity for most RNA viruses and have promise
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …
[HTML][HTML] Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies
Immediately from the outset of the COVID-19 pandemic, researchers from diverse
biomedical and biological disciplines have united to study the novel pandemic virus, SARS …
biomedical and biological disciplines have united to study the novel pandemic virus, SARS …
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
YM Loo, PM McTamney, RH Arends… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …
vaccines, there remains a need for more prevention and treatment options for individuals …